A recent study examined the efficacy of an experimental cholesteryl ester transfer protein inhibitor for lowering major adverse cardiovascular events in patients with high-risk vascular disease.
The American Association of Clinical Endocrinologists and the American College of Endocrinology have released new guidelines for the treatment and management of dyslipidemia and the prevention of...
In a recent expert-led presentation at the Practial Updates in Primary Care Virtual Series, Seth S. Martin, MD, MHS, and Daniel E. Soffer, MD, reviewed current evidence and clinical strategies for using...
A recent report from a non-profit, independant research group addresses the cost-effectiveness and budgetary impact of treatment with PCSK9 inhibitors.
An FDA advisory committee has voted to recommend approval of a new drug for the long-term treatment of patients with hypercholesterolemia and dyslipidemia.
